Get the Stockscreener App
4.98
1.43%
0.07
After Hours:
4.98
Insight Molecular Diagnostics Inc stock is traded at $4.98, with a volume of 186.33K.
It is up +1.43% in the last 24 hours and up +57.10% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
See More
Previous Close:
$4.91
Open:
$4.86
24h Volume:
186.33K
Relative Volume:
0.67
Market Cap:
$160.79M
Revenue:
$4.06M
Net Income/Loss:
$-50.22M
P/E Ratio:
-3.0769
EPS:
-1.6185
Net Cash Flow:
$-25.37M
1W Performance:
+8.73%
1M Performance:
+57.10%
6M Performance:
-41.27%
1Y Performance:
+0.00%
1-Day Range:
$4.71
$5.19
1-Week Range:
$4.4598
$5.19
52-Week Range:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
4.98 | 158.53M | 4.06M | -50.22M | -25.37M | -1.6185 |
TMO
Thermo Fisher Scientific Inc
|
459.30 | 168.20B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
166.26 | 117.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
533.92 | 41.97B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
352.21 | 34.17B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.90 | 31.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
MSN Money - msn.com
Number of shareholders of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
IMDX: Insight Molecular Diagnostics Inc.Comparative Chart - Zacks Investment Research
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
iMDx will post quarterly results May 13, then take investor questions live - Stock Titan
iMDx to Release First Quarter 2026 Results on May 13, 2026 - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS), Pfizer (PFE) and Travere Therapeutics (TVTX) - The Globe and Mail
Insight Molecular Corrects Bylaws Disclosure in Annual Report - TipRanks
IMDX (NASDAQ: IMDX) outlines 2026 proxy votes, FDA dd-cfDNA strategy - Stock Titan
[8-K] Insight Molecular Diagnostics Inc. Reports Material Event - Stock Titan
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones - Yahoo Finance
Broadwood Partners, Neal C. Bradsher buy $2.03m of Insight Molecular Diagnostics - Investing.com India
Broadwood and Neal Bradsher hold 39.7% of Insight Molecular (IMDX) shares - Stock Titan
Broadwood entities add 570K IMDX shares, hold 12.7M plus warrants - Stock Titan
Insight Molecular Diagnostics Inc. Q4 2025 earnings preview - MSN
Insight Molecular Diagnostics prices $26M registered direct offering; shares down - MSN
Major Investor Makes Bold Move Into Insight Molecular Diagnostics - TipRanks
Broadwood Partners buys $652,875 in Insight Molecular Diagnostics By Investing.com - Investing.com South Africa
Broadwood Partners buys $652,875 in Insight Molecular Diagnostics - Investing.com
Broadwood boosts Insight Molecular (IMDX) stake with 182,861-share buy - Stock Titan
Insight (IMDX) Stock Range-Bound (Marginal Loss) 2026-04-20Gap Down Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Stock List: Research Stocks from Around the World - GuruFocus
IMDX: GraftAssure's decentralized PCR test drives transplant diagnostics innovation and market expansion - TradingView
IMDX: GraftAssure aims to transform transplant diagnostics with decentralized, high-margin testing - TradingView — Track All Markets
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Kidney transplant test data heads to 3 global medical meetings - Stock Titan
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay - GlobeNewswire
Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst - Yahoo Finance
IMDX Options Volatility — NASDAQ:IMDX - TradingView
IMDX Options Chain — NASDAQ:IMDX - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Capital expenditures of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
IMDX Technical Analysis & Stock Price Forecast - Intellectia AI
Insight Molecular Diagnostics Inc. Stock Forecast Summary - Meyka
IMDX Submits Kitted Transplant Rejection Test for FDA Review - Clinical Lab Products
BTIG reiterates Neutral rating on Insight Molecular stock By Investing.com - Investing.com Canada
BTIG reiterates Neutral rating on Insight Molecular stock - Investing.com
Insight Molecular (IMDX) Soars 22.36% During Intraday Rally — What’s Driving the Market Turbulence? - Bitget
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):